Journal of Psychiatry and Neuroscience 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Navigated and individual α-peak-frequency-guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
CONCLUSION: Navigated αTMS to the left DLPFC reduced total, general psychopathological, and cognitive-disorganized symptoms of schizophrenia. These results provide evidence for the therapeutic efficacy of individual α-peak-frequency-guided rTMS in treatment-refractory schizophrenia.CLINICAL TRIAL REGISTRATION: NCT01941251; ClinicalTrials.gov.PMID:38428970 | PMC:PMC10914400 | DOI:10.1503/jpn.230063 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: Heli Tuppurainen Sara M äättä Mervi K önönen Petro Julkunen Hannu Kautiainen Soile Hyv ärinen Olli Vaurio Mikko Joensuu Matti Vanhanen Kati Aho-Mustonen Esa Mervaala Jari Tiihonen Source Type: research
Lessons from studies of medication reduction in psychosis: giving participants accurate information about risk in psychiatric research trials
J Psychiatry Neurosci. 2024 Mar 1;49(2):E81-E86. doi: 10.1503/jpn.230137. Print 2024 Jan-Feb.ABSTRACTAll research needs ethical regulation, which is institutionalized in research ethics committees. The patient information sheet, approved by a research ethics committee, sets out what patients need to know to make an informed choice about research participation. However, guidance from research ethics committees is much less explicit about risk communication. In this commentary, the balance of risk in the patient information sheets from protocols of 2 randomized controlled trials (RCTs) of medication reduction in psychosis wa...
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: David Foreman Source Type: research
Navigated and individual α-peak-frequency-guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
CONCLUSION: Navigated αTMS to the left DLPFC reduced total, general psychopathological, and cognitive-disorganized symptoms of schizophrenia. These results provide evidence for the therapeutic efficacy of individual α-peak-frequency-guided rTMS in treatment-refractory schizophrenia.CLINICAL TRIAL REGISTRATION: NCT01941251; ClinicalTrials.gov.PMID:38428970 | PMC:PMC10914400 | DOI:10.1503/jpn.230063 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: Heli Tuppurainen Sara M äättä Mervi K önönen Petro Julkunen Hannu Kautiainen Soile Hyv ärinen Olli Vaurio Mikko Joensuu Matti Vanhanen Kati Aho-Mustonen Esa Mervaala Jari Tiihonen Source Type: research
Lessons from studies of medication reduction in psychosis: giving participants accurate information about risk in psychiatric research trials
J Psychiatry Neurosci. 2024 Mar 1;49(2):E81-E86. doi: 10.1503/jpn.230137. Print 2024 Jan-Feb.ABSTRACTAll research needs ethical regulation, which is institutionalized in research ethics committees. The patient information sheet, approved by a research ethics committee, sets out what patients need to know to make an informed choice about research participation. However, guidance from research ethics committees is much less explicit about risk communication. In this commentary, the balance of risk in the patient information sheets from protocols of 2 randomized controlled trials (RCTs) of medication reduction in psychosis wa...
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: David Foreman Source Type: research
Navigated and individual α-peak-frequency-guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
CONCLUSION: Navigated αTMS to the left DLPFC reduced total, general psychopathological, and cognitive-disorganized symptoms of schizophrenia. These results provide evidence for the therapeutic efficacy of individual α-peak-frequency-guided rTMS in treatment-refractory schizophrenia.CLINICAL TRIAL REGISTRATION: NCT01941251; ClinicalTrials.gov.PMID:38428970 | PMC:PMC10914400 | DOI:10.1503/jpn.230063 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: Heli Tuppurainen Sara M äättä Mervi K önönen Petro Julkunen Hannu Kautiainen Soile Hyv ärinen Olli Vaurio Mikko Joensuu Matti Vanhanen Kati Aho-Mustonen Esa Mervaala Jari Tiihonen Source Type: research
Lessons from studies of medication reduction in psychosis: giving participants accurate information about risk in psychiatric research trials
J Psychiatry Neurosci. 2024 Mar 1;49(2):E81-E86. doi: 10.1503/jpn.230137. Print 2024 Jan-Feb.ABSTRACTAll research needs ethical regulation, which is institutionalized in research ethics committees. The patient information sheet, approved by a research ethics committee, sets out what patients need to know to make an informed choice about research participation. However, guidance from research ethics committees is much less explicit about risk communication. In this commentary, the balance of risk in the patient information sheets from protocols of 2 randomized controlled trials (RCTs) of medication reduction in psychosis wa...
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: David Foreman Source Type: research
Navigated and individual α-peak-frequency-guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
CONCLUSION: Navigated αTMS to the left DLPFC reduced total, general psychopathological, and cognitive-disorganized symptoms of schizophrenia. These results provide evidence for the therapeutic efficacy of individual α-peak-frequency-guided rTMS in treatment-refractory schizophrenia.CLINICAL TRIAL REGISTRATION: NCT01941251; ClinicalTrials.gov.PMID:38428970 | PMC:PMC10914400 | DOI:10.1503/jpn.230063 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: Heli Tuppurainen Sara M äättä Mervi K önönen Petro Julkunen Hannu Kautiainen Soile Hyv ärinen Olli Vaurio Mikko Joensuu Matti Vanhanen Kati Aho-Mustonen Esa Mervaala Jari Tiihonen Source Type: research
Lessons from studies of medication reduction in psychosis: giving participants accurate information about risk in psychiatric research trials
J Psychiatry Neurosci. 2024 Mar 1;49(2):E81-E86. doi: 10.1503/jpn.230137. Print 2024 Jan-Feb.ABSTRACTAll research needs ethical regulation, which is institutionalized in research ethics committees. The patient information sheet, approved by a research ethics committee, sets out what patients need to know to make an informed choice about research participation. However, guidance from research ethics committees is much less explicit about risk communication. In this commentary, the balance of risk in the patient information sheets from protocols of 2 randomized controlled trials (RCTs) of medication reduction in psychosis wa...
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: David Foreman Source Type: research
Navigated and individual α-peak-frequency-guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
CONCLUSION: Navigated αTMS to the left DLPFC reduced total, general psychopathological, and cognitive-disorganized symptoms of schizophrenia. These results provide evidence for the therapeutic efficacy of individual α-peak-frequency-guided rTMS in treatment-refractory schizophrenia.CLINICAL TRIAL REGISTRATION: NCT01941251; ClinicalTrials.gov.PMID:38428970 | DOI:10.1503/jpn.230063 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: Heli Tuppurainen Sara M äättä Mervi K önönen Petro Julkunen Hannu Kautiainen Soile Hyv ärinen Olli Vaurio Mikko Joensuu Matti Vanhanen Kati Aho-Mustonen Esa Mervaala Jari Tiihonen Source Type: research
Lessons from studies of medication reduction in psychosis: giving participants accurate information about risk in psychiatric research trials
J Psychiatry Neurosci. 2024 Mar 1;49(2):E81-E86. doi: 10.1503/jpn.230137. Print 2024 Jan-Feb.ABSTRACTAll research needs ethical regulation, which is institutionalized in research ethics committees. The patient information sheet, approved by a research ethics committee, sets out what patients need to know to make an informed choice about research participation. However, guidance from research ethics committees is much less explicit about risk communication. In this commentary, the balance of risk in the patient information sheets from protocols of 2 randomized controlled trials (RCTs) of medication reduction in psychosis wa...
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: David Foreman Source Type: research
Navigated and individual α-peak-frequency-guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia
CONCLUSION: Navigated αTMS to the left DLPFC reduced total, general psychopathological, and cognitive-disorganized symptoms of schizophrenia. These results provide evidence for the therapeutic efficacy of individual α-peak-frequency-guided rTMS in treatment-refractory schizophrenia.CLINICAL TRIAL REGISTRATION: NCT01941251; ClinicalTrials.gov.PMID:38428970 | DOI:10.1503/jpn.230063 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - March 1, 2024 Category: Psychiatry Authors: Heli Tuppurainen Sara M äättä Mervi K önönen Petro Julkunen Hannu Kautiainen Soile Hyv ärinen Olli Vaurio Mikko Joensuu Matti Vanhanen Kati Aho-Mustonen Esa Mervaala Jari Tiihonen Source Type: research
Ending the overdose epidemic by ending the war on drug users: Can this work?
J Psychiatry Neurosci. 2024 Feb 21;49(1):E77-E80. doi: 10.1503/jpn.240003. Print 2024 Jan-Feb.NO ABSTRACTPMID:38383036 | PMC:PMC10890790 | DOI:10.1503/jpn.240003 (Source: Journal of Psychiatry and Neuroscience)
Source: Journal of Psychiatry and Neuroscience - February 21, 2024 Category: Psychiatry Authors: Marco Leyton R Michael Krausz Source Type: research
